IFNA1 and Dravet syndrome: Our results indicate that tofacitinib does not fully suppress the immune response in people with DS, but rather attenuates IFN scores and cytokine scores to levels observed in the general population, which is an important consideration given the likely requirement for long-term use of the drug in this population.